344 related articles for article (PubMed ID: 22729611)
41. Efficacy and safety of bevacizumab combined with EGFR-TKIs in advanced non-small cell lung cancer: A meta-analysis.
Yang Y; Wang L; Li X; Zhang S; Yu J; Nie X; Liu W; Wu X; Zhang P; Li Y; Li A; Ai B
Thorac Cancer; 2022 Jan; 13(1):31-37. PubMed ID: 34859599
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.
Tian W; Ding W; Kim S; Zheng L; Zhang L; Li X; Gu J; Zhang L; Pan M; Chen S
PLoS One; 2013; 8(7):e67929. PubMed ID: 23861835
[TBL] [Abstract][Full Text] [Related]
43. Effect of smoking habits on the efficacy of EGFR-TKI plus anti-angiogenic agent in advanced EGFR-mutant NSCLC.
Qin BD; Jiao XD; Wang Y; Wu Y; Ling Y; Liu K; Zang YS
Lung Cancer; 2022 Aug; 170():91-97. PubMed ID: 35728482
[TBL] [Abstract][Full Text] [Related]
44. The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC).
Yang J; He J; Yu M; Li T; Luo L; Liu P
Medicine (Baltimore); 2016 Dec; 95(50):e5599. PubMed ID: 27977596
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
46. The efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: a systematic review and meta-analysis.
Sheng J; Yang Y; Ma Y; Yang B; Zhang Y; Kang S; Zhou T; Hong S; Qin T; Hu Z; Fang W; Huang Y; Zhang L
PLoS One; 2015; 10(6):e0127306. PubMed ID: 26034985
[TBL] [Abstract][Full Text] [Related]
47. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
[TBL] [Abstract][Full Text] [Related]
48. Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer: A systematic review and meta-analysis.
Elgebaly A; Menshawy A; El Ashal G; Osama O; Ghanem E; Omar A; Negida A
Breast Dis; 2016 Jul; 36(2-3):91-101. PubMed ID: 27612040
[TBL] [Abstract][Full Text] [Related]
49. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
Lee CK; Davies L; Wu YL; Mitsudomi T; Inoue A; Rosell R; Zhou C; Nakagawa K; Thongprasert S; Fukuoka M; Lord S; Marschner I; Tu YK; Gralla RJ; Gebski V; Mok T; Yang JC
J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28376144
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Zhang M; Guo H; Zhao S; Wang Y; Yang M; Yu J; Yan Y; Wang Y
Oncotarget; 2016 Jun; 7(26):39823-39833. PubMed ID: 27223081
[TBL] [Abstract][Full Text] [Related]
51. The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis.
Wu FZ; Song JJ; Zhao ZW; Huang XF; Mao JT; Tu JF; Chen MJ; Chen WQ; Fang SJ; Zheng LY; Fan XX
Math Biosci Eng; 2019 Aug; 16(6):7921-7933. PubMed ID: 31698647
[No Abstract] [Full Text] [Related]
52. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC.
Li YX; Yang JY; Xu YF; Zhang M; Zhang XP; Chen WY; Lv XD
Math Biosci Eng; 2019 Jun; 16(5):5687-5696. PubMed ID: 31499732
[No Abstract] [Full Text] [Related]
53. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Fan Y; Huang ZY; Yu HF; Luo LH
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
[TBL] [Abstract][Full Text] [Related]
54. Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Li M; Zhang Q; Fu P; Li P; Peng A; Zhang G; Song X; Tan M; Li X; Liu Y; Wu Y; Fan S; Wang C
PLoS One; 2012; 7(5):e37229. PubMed ID: 22615946
[TBL] [Abstract][Full Text] [Related]
55. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y
Medicine (Baltimore); 2018 Aug; 97(33):e11936. PubMed ID: 30113497
[TBL] [Abstract][Full Text] [Related]
56. [Effectiveness of EGFR-TKIs versus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a meta-analysis].
Cao F; Zhang L; Wang S; Zhong D; Wang Y
Zhongguo Fei Ai Za Zhi; 2015 Mar; 18(3):146-54. PubMed ID: 25800570
[TBL] [Abstract][Full Text] [Related]
57. First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Wu Q; Luo W; Li W; Wang T; Huang L; Xu F
Front Oncol; 2021; 11():598265. PubMed ID: 33928022
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials.
Li X; Wang H; Lin W; Xu Q
Curr Med Res Opin; 2014 Nov; 30(11):2295-304. PubMed ID: 24701984
[TBL] [Abstract][Full Text] [Related]
59. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.
Gao G; Ren S; Li A; Xu J; Xu Q; Su C; Guo J; Deng Q; Zhou C
Int J Cancer; 2012 Sep; 131(5):E822-9. PubMed ID: 22161771
[TBL] [Abstract][Full Text] [Related]
60. The evaluation of efficacy and safety of sunitinib on EGFR-TKI pretreated advanced non-small cell lung cancer patients in China.
Liu YR; Zhu W; Zhang JL; Huang JQ; Zhao YZ; Zhang W; Han BH; Yao YH; Jiang LY; Li SQ
Clin Respir J; 2014 Apr; 8(2):206-12. PubMed ID: 24118906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
